Skip to main content

Week In Review: Innovent Acquires Novel Atopic Dermatitis Treatment In $267 Million Pact

Suzhou Innovent Bio acquired China rights to an atopic dermatitis therapy developed by Denmark's Union Therapeutics in a $267 million agreement. Innovent will pay $20 million upfront and make up to $247 million in milestones, plus royalties.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.